Phase 2 N=31 AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
Advanced Malignant Solid Neoplasm · Refractory Malignant Solid Neoplasm
Primary: Objective Response Rate (ORR) — 27 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
Non-small Cell Lung Cancer
Primary: Tumor Response by Direct RECIST Measurement — 0 participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=141 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Adult Solid Tumor · Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Response Rates — 4; 0; 0; 0 Participants
Phase 1 N=74 A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Neoplasms · Lymphoma, Non-Hodgkin
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 2; 0 participants
Phase 2 N=70 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Breast Cancer
Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF
N/A N=367 Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Gastric Cancer, Gastroesophageal Junction Cancer
Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…
Phase 2 N=106 LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Tumors With CDK4/6 Pathway Activation
Primary: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments — 0; 3; 16; 71 Participants
Phase 3 N=41 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
CCND1 Gene Amplification · CCND2 Gene Amplification · CCND3 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 6 percentage of participants
Phase 2 N=29 Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Advanced Gastrointestinal Stromal Tumors
Primary: Number of Participants With Non Progression at 4 Months — 3 Participants
Phase 2 N=72 Phase II Trial for Large ER-Negative Breast Cancers
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Phase 1 N=16 MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
Breast Neoplasms
Primary: Incidence of Treatment-emergent AE's — 16 participants
Phase 2 N=34 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Oligodendroglioma · Oligoastrocytoma
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 21 Percentage of participants
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 2 N=40 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Phase 1 N=20 A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Her2 Amplified Solid Tumors · Metastatic Breast Cancer
Primary: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose — NA mg/kg
Phase 2 N=68 Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 10.7; 15.0; 25.0; 0.0 percentage of participants — p=0.94
Phase 2 N=12 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Phase 2 N=55 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Phase 2 N=56 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants
Phase 2 N=265 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Glioblastoma
Primary: Overall Survival (OS) Time — 16.3; 14.5; 13.4 Months — p=0.0328
Phase 2 N=27 A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Advanced Cancers
Primary: Progression-Free Rate at 4 Month — 25; 10; 44.4; 75 percentage of participants
Phase 2 N=56 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Breast Neoplasms
Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants
Phase 3 N=545 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
Glioblastoma
Primary: Overall Survival (OS) Time — 26.3; 26.3 Months — p=0.8623
Phase 2 N=181 A Study of ZN-c5 in Subjects With Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate (CBR) for ZN-c5 as a Monotherapy — 7; 0; 1; 1 Participants
Phase 2 N=6 Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Diffuse Large B Cell Lymphoma
Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants
Phase 2 N=23 Lung-MAP S1400K: c-MET Positive
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC V7
Primary: Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA) — 9 percentage of participants
Phase 2 N=24 Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Triple Negative Breast Cancer · Breast Cancer
Primary: Immune-based Mechanism of Action — 0.3 CD8+/Tregs ratio — p=0.101
Phase 2 N=327 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) — 2.8; 2.9 months — p=0.761
Phase 2 N=121 Phase II ABT-888 With Cyclophosphamide
Ovarian Cancer · Primary Peritoneal Cancer · Serous Carcinoma Cancer
Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants